Cryoport CEO Jerrell Shelton sells $2.3 million in CYRX stock

Published 21/06/2025, 01:20
Cryoport CEO Jerrell Shelton sells $2.3 million in CYRX stock

Cryoport, Inc. (NASDAQ:CYRX), a $319 million market cap company, saw its President and CEO Jerrell Shelton sell a total of 339,720 shares of common stock between June 17 and June 20, 2025. The sales, executed under a pre-arranged trading plan, resulted in proceeds of $2,289,781. The shares were sold at weighted average prices ranging from $6.4732 to $6.812. According to InvestingPro data, the stock has shown significant volatility with a beta of 1.84, trading between $4.58 and $9.93 over the past 52 weeks.

Shelton also exercised options to acquire a total of 389,720 shares of Cryoport common stock at an exercise price of $5.00 per share, for a total value of $1,948,600. InvestingPro analysis indicates the stock currently trades below its Fair Value, with analysts setting price targets ranging from $6.50 to $15.00 per share.

Following these transactions, Shelton directly owns 912,419 shares of Cryoport, Inc. For deeper insights into Cryoport’s valuation and financial health metrics, including 6 additional ProTips and comprehensive analysis, check out the detailed Pro Research Report available on InvestingPro.

In other recent news, Cryoport, Inc. has announced the completion of its sale of the specialty courier business, CRYOPDP, to DHL Group for approximately $200 million in cash. This transaction is part of a strategic partnership aimed at enhancing supply chain services for the global life sciences and healthcare sectors. The sale provides Cryoport with additional capital to focus on advancing its Life Science Services platform, particularly in the regenerative medicine market. Meanwhile, Cryoport reported its first-quarter 2025 earnings, revealing an earnings per share (EPS) of -$0.28, which surpassed the forecasted -$0.31. However, the company missed revenue expectations, generating $41 million against a forecast of $58.96 million. Despite this, Cryoport’s life sciences services revenue rose by 17%, with commercial cell and gene therapies growing by 33%. Cryoport has confirmed its full-year 2025 revenue guidance of $165-$172 million, representing a 7.5% growth at the midpoint. The strategic partnership with DHL is expected to enhance Cryoport’s global logistics capabilities, particularly in the Asia Pacific and EMEA regions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.